EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Validation of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Coding in US Claims Data

Joshua U Okonkwo, Erika K Williams, Reza Sadjadi, Sebastian Schneeweiss iD, Colin Anderson-Smits, Hakan Ay, William Spalding, Priyanka Anand iD, Zhigang Lu, Kueiyu Joshua Lin iD

Pharmacoepidemiology and Drug Safety · 2025

DOI: 10.1002/pds.70123 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Joshua U Okonkwo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Electronic Health Records, Clinical Coding, Insurance Claim Review. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare autoimmune condition of the peripheral nervous system. The validity of the CIDP diagnosis code in claims data is unclear.

Methods

We conducted a validation study testing the performance of claims‐based algorithms in identifying CIDP cases, using electronic health record data from the Mass General Brigham Integrated Health Care System linked with Medicare claims data from 01/01/2008 to 12/31/2020. The algorithms require a record of intravenous immunoglobulin (IVIG) use and International Classification of Diseases 9th/10th Revision (ICD9/10) CIDP codes before (including) the date of IVIG use. The positive predictive values (PPVs) of each claims‐based algorithm were calculated against the reference standard for CIDP and chronic immune‐mediated acquired neuropathy established through chart review by two board‐certified neurologists using a standardized abstraction tool.

Results

The study cohort consisted of 140 patients (59 in the ICD9 and 81 in the ICD10 era). The PPV of the algorithm requiring at least one CIDP diagnosis code before IVIG use was 66.2% (95% confidence interval [CI], 58.0–74.3). The PPV improved to 71.2% (62.7–79.6) when requiring at least two CIDP codes before IVIG use. The PPV for patients with at least one CIDP code who met the European Academy of Neurology/Peripheral Nerve Society 2021 diagnostic criteria was 30.0% (22.1–37.9).

Conclusion

We found that a patient cohort identified using claims‐based CIDP diagnoses included a substantial number of patients with other chronic inflammatory acquired neuropathies not formally recognized as CIDP by clinical consensus criteria. Requiring two CIDP codes can improve PPVs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingElectronic Health RecordsClinical CodingInsurance Claim ReviewHumansUnited StatesInternational Classification of DiseasesImmunoglobulins, IntravenousAlgorithmsMaleAgedFemaleMedicareAged, 80 and overMiddle AgedDatabases, FactualPredictive Value of Tests

Stichwörter der Autor:innen

chronic immune‐mediated acquired neuropathychronic inflammatory demyelinating polyradiculoneuropathyclaims‐based algorithm validationintravenous immunoglobulin

Substanzen

Immunoglobulins, Intravenous

Autor:innen und Institutionen

  • Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Clinical Phenotyping and Outcome Validation Program, Mass General Brigham Center for Integrated Healthcare Data Research, Boston, Massachusetts, USA.
  • Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.

ORCID-Profile: Sebastian Schneeweiss, Priyanka Anand, Kueiyu Joshua Lin

Förderung

  • Takeda Pharmaceutical Company

Zitieren

APA

Okonkwo, J. U., Williams, E. K., Sadjadi, R., Schneeweiss, S., Anderson-Smits, C., Ay, H., Spalding, W., Anand, P., Lu, Z., & Lin, K. J. (2025). Validation of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Coding in US Claims Data. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70123

Vancouver

Okonkwo JU, Williams EK, Sadjadi R, Schneeweiss S, Anderson-Smits C, Ay H, et al. Validation of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Coding in US Claims Data. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70123

BibTeX
@article{Okonkwo2025,
  author = {Okonkwo, Joshua U and Williams, Erika K and Sadjadi, Reza and Schneeweiss, Sebastian and Anderson-Smits, Colin and Ay, Hakan and Spalding, William and Anand, Priyanka and Lu, Zhigang and Lin, Kueiyu Joshua},
  title = {Validation of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Coding in US Claims Data},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  doi = {10.1002/pds.70123}
}
Kostenlos starten →